Although the DNA methylation levels of different CG sites in the CDKN1C promoter are distinct (BSP1 and BSP2 positions), significantly increased methylation of CDKN1C in the same region was detected in AML cells, when compared with healthy control cells. Here, CDKN1C is linked to acute myeloid leukemia.